Cambridge startup Editas plans to test IPO market for biotechs

Robert Weisman.  The Boston Globe. January 5th, 2016 https://www.bostonglobe.com/business/2016/01/04/cambridge-startup-editas-plans-test-ipo-market-for-biotechs/uqK7XseLzbLNTtH5ENJ7bM/story.html.

Editas Medicine Inc. has filed for an IPO worth up to $100 million in stock.  Editas was founded in 2013 to develop CRISPR/Cas9 technology licensed from the Broad Institute for medical therapies and raised $120 million in private investments last August.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply